Sanjay Shukla - 09 Jan 2026 Form 4 Insider Report for aTYR PHARMA INC (ATYR)

Reporting relationship: President and CEO, Director
Issuer ticker: ATYR
Reported as of: 09 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jan 2026, 17:46:19 UTC
Prior SEC filing: 04 Feb 2025
Next SEC filing: 04 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Nancy E. Denyes, attorney-in-fact

Key filing fact

Sanjay Shukla filed Form 4 for aTYR PHARMA INC (ATYR) on 09 Jan 2026.

Key facts

This page summarizes Sanjay Shukla's Form 4 filing for aTYR PHARMA INC (ATYR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jan 2026, 17:46.

Change

Previous filing in this sequence was filed on 04 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001671026 Primary reporting owner

Shukla Sanjay

Relationship: President and CEO, Director
Address: 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO
Signature: /s/ Nancy E. Denyes, attorney-in-fact
Signature date: 09 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATYR transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +1,500,000
Change %
Price: $0.000000
Shares after: 1,500,000
Date: 09 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,500,000
Exercise price: $0.7127
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning February 9, 2026, such that this option will be fully exercisable on January 9, 2029. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.